Provided by Tiger Fintech (Singapore) Pte. Ltd.

Equillium Inc.

0.4727
+0.00370.79%
Post-market: 0.47270.00000.00%18:24 EDT
Volume:171.28K
Turnover:80.46K
Market Cap:16.83M
PE:-2.07
High:0.5298
Open:0.4602
Low:0.4312
Close:0.4690
Loading ...

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
01 Apr

EQ Resources Says Non-Executive Chairman to Become Executive Chairman on Interim Basis

MT Newswires Live
·
01 Apr

EQ Resources Strengthens Leadership Team with Key Appointments

TIPRANKS
·
01 Apr

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Simply Wall St.
·
31 Mar

Equillium Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
28 Mar

Equillium Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
28 Mar

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3

MT Newswires Live
·
28 Mar

Equillium Inc : Leerink Partners Cuts to Market Perform From Outperform

THOMSON REUTERS
·
28 Mar

Equillium downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
28 Mar

Equillium Inc : Leerink Partners Cuts Target Price to $1 From $3

THOMSON REUTERS
·
28 Mar

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results

Benzinga
·
28 Mar

Equillium reports EQUATOR study did not improve complete, overall response rates

TIPRANKS
·
27 Mar

BRIEF-Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease

Reuters
·
27 Mar

BRIEF-Equillium Reports Fourth Quarter and FY 2024 Results

Reuters
·
27 Mar

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

THOMSON REUTERS
·
27 Mar

Equillium Inc - Breakthrough Therapy Designation Request Submitted to FDA, Feedback Expected During May 2025

THOMSON REUTERS
·
27 Mar

Equillium Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients With Acute Graft-Versus-Host Disease

THOMSON REUTERS
·
27 Mar

Equillium Inc - Itolizumab Did Not Improve Response Rates at Day 29

THOMSON REUTERS
·
27 Mar

Equillium Inc - Itolizumab Achieved Statistical Significance in Longer-Term Outcomes

THOMSON REUTERS
·
27 Mar

Equillium Q4 Revenue USD 4.392 Million

THOMSON REUTERS
·
27 Mar